Table 2.
Comparison of clinical parameters after fenofibrate treatment for 12 and 24 weeks in patients with hypertriglyceridemia (n = 83).
| Parameters | Baseline | 12 weeks | 24 weeks |
|---|---|---|---|
| Age, y | 44.68 ± 10.51 | ||
| Gender, M/F | 50/32 | ||
| WC, cm | 93.00 ± 7.78 | 92.32 ± 7.26 | 91.27 ± 7.59∗ |
| BMI, kg/m2 | 25.67 ± 3.11 | 25.29 ± 3.44 | 25.08 ± 3.35∗ |
| TC, mmol/L | 5.34 ± 0.68 | 5.11 ± 0.94 | 5.12 ± 0.66 |
| LDL-C, mmol/L | 2.79 ± 0.75 | 3.10 ± 0.72 | 3.02 ± 0.61 |
| HDL-C, mmol/L | 1.03 ± 0.18 | 1.29 ± 0.27∗ | 1.40 ± 0.27∗∗ |
| TG, mmol/L | 2.70 (1.93–3.56) | 1.75 (1.47–2.00)∗∗ | 1.63 (1.21–2.04)∗∗ |
| FBG, mmol/L | 5.43 ± 0.49 | 5.45 ± 0.50 | 5.33 ± 0.46 |
| FINS, mIU/L | 14.40 (8.85–23.45) | 12.80 (8.90–17.10) | 10.40 (7.10–15.40)∗ |
| HOMA-IR | 3.26 (2.53–5.18) | 2.59 (1.98–3.85)∗ | 2.42 (1.46–4.12)∗ |
| HOMA-β | 124.31 (65.45–194.17) | 110.00 (45.38–131.58)∗ | 95.10 (48.75–123.07)∗∗ |
Data are means ± SD unless indicated otherwise. TG, FINS, hsCRP, HOMA-IR, and HOMA-β are shown as medians and upper and lower quartiles. WC: waist circumference; BMI: body mass index; TC: total cholesterol; LDL-C: low-density lipoprotein cholesterol; HDL-C: high-density lipoprotein cholesterol; TG: triglyceride; FBG: fasting blood glucose; FINS: fasting insulin; HOMA-IR: homeostasis model assessment of insulin resistance; HOMA-β: homeostasis model assessment of β-cell function. ∗Significantly different at P < 0.05 versus baseline; ∗∗significantly different at P < 0.01 versus baseline.